Multidisciplinary Treatment and Research of Pancreatic Cancer
10:10 - 10:30, Room 104 (104講堂)
Multidisciplinary treatment and research of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the third (at presence) and will be the second (in 2030) leading cancer death in western countries with only an unsatisfying improvement in 5-year survival rates during last decades, from 4% in 1999 to 8.5% in 2018 when considering all stages. Reasons for poor outlook of pancreatic cancer include diagnosis at late stage and refractory to chemotherapy-, radiotherapy, targeted therapy, and immunotherapy. At presence, operation remains to be the only potentially curative treatment modality for PDAC. However, after a potential curative resection, more than 70% of patients have recurrences. The high prevalence of residual disease after potential curative resection justify systemic therapy. Many prospective randomized trials reported better survivals for patients with adjuvant therapy after resection of their PDAC. Besides, there are more and more recent reports of conversion operation after down-staging unresectable or even metastatic PDAC by systemic therapy. Multidisciplinary approach will be the most promising treatment for pancreatic cancer.